Amber Tong on Muck Rack

Amber Tong

Verified
Hong Kong
As seen in: Bloomberg News, MSN, MSN Singapore, Bloomberg Green Daily, Cinco Días, MSN España, MSN Philippines, Yahoo Singapore, Yahoo Finance, Yahoo Finance Canada, Yahoo Finance Singapore and
Covering China biotech and pharma @business | formerly @endpts | views are my own | say hi: ptong38@bloomberg.net
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Amber

Contact Amber, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Chinese pharma contractor under watch: Pentagon names WuXi AppTec on military list

|
By Gerry Smith , Amber Tong 
| ThePrint
Any restriction that stems from the designation could have broader implications because WuXi AppTec helps conduct research and development efforts on behalf of many US drugmakers. That includes a disproportionate impact on small- and mid-cap biotech companies that tend to rely on low-cost, high-quality Chinese service providers, Humphrey wrote in a note.
Open in Who Shared View Duplicates (9) Issue with article?

Pfizer-Partnered Obesity Drugmaker Eyes Deals Outside China

|
By Amber Tong 
| Bloomberg Tax
is in “deep discussions” to expand its weight-loss drug beyond China, buoyed by new clinical data that shows the therapy helped patients lose more weight than ’s Wegovy. Sciwind is pursuing agreements in both major Western markets and fast-growing emerging markets to fully capture the drug’s commercial potential, Chief Executive Officer said in an interview. The drug, ecnoglutide, is currently only in China, where acquired exclusive local rights for up to $495 million.
Open in Who Shared Issue with article?

Pfizer-Partnered Obesity Drugmaker Eyes Deals Outside China

|
By Amber Tong 
| Bloomberg Law
is in “deep discussions” to expand its weight-loss drug beyond China, buoyed by new clinical data that shows the therapy helped patients lose more weight than ’s Wegovy. Sciwind is pursuing agreements in both major Western markets and fast-growing emerging markets to fully capture the drug’s commercial potential, Chief Executive Officer said in an interview. The drug, ecnoglutide, is currently only in China, where acquired exclusive local rights for up to $495 million.
Open in Who Shared Issue with article?
See all 2,928 licensed articles (3,079 Total)

Actions

Share this page

Get in touch with Amber

Contact Amber, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified